Strategic Initiative

Slingshot members are tracking this corporate initiative:

Novartis(NVS) to acquire The Medicines Company(MDCO) for USD 9.7 bn, adding inclisiran, investigational cholesterol-lowering therapy

Source Link:
https://www.novartis.com/news/media-releases/novartis-acquire-medicines-company-usd-97-bn-adding-inclisiran-potentially-transformational-investigational-cholesterol-lowering-therapy-address-leading-global

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
Importance
High Medium Low
Impact on Stocks
NVS
100%
ARWR
100%
MDCO
100%
SIGN ME UP
I want to vote! LOG ME IN
Now!

Additional Information

Additional Relevant Details
  • Offer price of USD 85.00 per share in cash represents a premium of approximately 41% over The Medicines Company’s 30-day volume weighted average price of USD 60.33; valuing the company at approximately USD 9.7 billion on a fully diluted basis
https://www.novartis...
Slingshot Insights Explained
JOIN FOR FREE TODAY
Strategic Initiative Date
Announcement Date:
Nov 24, 2019
Projected Implementation:
Q4, 2019
Relevance Tracked Until:
Q1, 2020
Related Projects Image

  • Don’t see a project related to the strategic initiative you care about?

Related Keywords Inclisiran, Cholesterol Lowering
About Us
Media Center
Connect with Us
© 2024 Slingshot Insights. All rights reserved.